Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Florida prior auth and notification Policy …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    H1036-280 Humana Fully Integrated Florida prior authorization and notification list

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medications and certain services that require prior authorization or notification for Humana Fully Integrated Florida HMO D-SNP Medicare Advantage members and explains how providers should request authorization and what information is required.

    Policy Summary
    PayerHumana
    PolicyH1036-280 Humana Fully Integrated Florida prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests online via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), or by fax to 888-447-3430 and include required patient, billing and clinical information.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3submission methods
    90new member grace period (days)
    6max diagnosis codes
    ManyNDC required on claims
    20+ pagesmed list length

    Coverage and Authorization Overview

    Coverage stance and criteria overview

    Medications and services on this list require prior authorization and must meet Medicare coverage and medical necessity standards; step therapy and preferred drug lists may apply for certain Part B medications.

    Services must be provided according to Medicare coverage guidelines and be medically necessary.
    Some medications are subject to step therapy; Humana's Medicare Part B Step Therapy Preferred Drug List identifies preferred and nonpreferred medications and cross-benefit strategies.
    Certain HCPCS codes require a corresponding NDC to be billed on claims (shared HCPCS and not otherwise classified codes).
    Transplant-related preauthorizations are reviewed by the Humana National Transplant Network with specified contact methods.
    Urgent/emergent services do not require referrals or prior authorizations.
    Policy Summary
    PayerHumana
    PolicyH1036-280 Humana Fully Integrated Florida prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests online via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), or by fax to 888-447-3430 and include required patient, billing and clinical information.
    SourceLink
    On This Page
    Coverage and Authorization OverviewBilling Codes and Diagnosis LimitsHow to Request Authorization and Provider ResponsibilitiesDefinitions and Flag Legend

    Summary of authorization stance

    Medications listed require preauthorization/notification; specific clinical criteria are not included in these chunks.

    List entries: Each medication entry pairs brand and generic names with corresponding HCPCS/Q-codes or other billing codes and may include submission flags (for example: *, †, ‡, **, ††).

    Prior authorization/notification entries and special requirements

    Medications listed require prior authorization or notification; specific flags modify submission and billing requirements.

    Drug entry elements: Each drug entry includes brand and generic names, associated billing code(s), and may include one or more flags: * (new PA requirement), † (new-to-market), ‡ (NDC billing requirement for shared HCPCS/C9399), ** (step therapy required), †† (transplant review).
    NDC billing requirement: Entries marked with ‡ indicate that all shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
    Step therapy flag: Entries marked with ** require step therapy through a Humana-preferred drug as part of preauthorization.
    Transplant review routing: Entries marked with †† indicate preauthorization requests will be reviewed by the Humana National Transplant Network; submission methods include fax, phone, or email with specified hours.

    Administrative listing and flags

    Catalog of blood‑clotting factor products with associated HCPCS codes and administrative flags; providers must follow preauthorization and billing instructions.

    Product listing: Blood‑clotting factor products are listed by brand with generic descriptor and associated HCPCS/J billing code(s).
    Administrative flags: Many factor products are annotated with flags (for example ‡ and **) that indicate billing/NDC requirements or step therapy; some entries are noted as new preauthorization requirements or new‑to‑market additions (* and †).
    Provider requirement: Providers must obtain prior authorization or provide notification per the list and must bill shared HCPCS/C9399 entries with the corresponding NDC where indicated.

    Billing Codes and Diagnosis Limits

    Representative HCPCS/Q codesmixed
    Q2055idecabtagene vicleucel (Abecma) - example HCPCS/Q-code shown
    J9264paclitaxel protein-bound (Abraxane) - example J-code shown
    Covered HCPCS CodesHCPCSCovered
    J9331sirolimus protein-bound particles for injectable suspension
    J9307pralatrexate
    J2506pegfilgrastim (Neulasta)
    J1745infliximab
    Sample HCPCS CodesHCPCS
    J1449billing code listed for an item in the list
    J9318billing code listed for romidepsin
    J0596billing code listed for Ruconest
    Blood-clotting factor HCPCS CodesHCPCS
    J7192Assigned to multiple antihemophilic factor products (e.g., Advate, Kogenate FS, Recombinate)
    J7207Adynovate (antihemophilic factor [recombinant], PEGylated)
    J7210Afstyla (antihemophilic factor [recombinant] single chain)
    J7173Alhemo (concizumab-mtci)
    J7186Alphanate (antihemophilic factor/von Willebrand factor complex [human])
    J7193AlphaNine SD (coagulation factor IX [human])
    J7201Alprolix (coagulation factor IX [recombinant])
    J7214Altuviiio (efanesoctocog alfa)
    J1414Beqvez (fidanacogene elaparvovec-dzkt)
    J7175Coagadex (coagulation factor X [human])
    1–10 of 34
    1/4
    inv-09: diagnosis code limit
    Diagnosis code limitUp to a maximum of 6 diagnosis codes per authorization request
    ContextRequested diagnosis codes are included with required PA information (patient identifiers, date of service, HCPCS and diagnosis codes)
    Where statedCoding thresholds section of the prior authorization list
    inv-10: NDC requirement for shared HCPCS/NOC codes
    NDC requirement (shared HCPCS/NOC)All shared HCPCS codes and not otherwise classified (NOC/C9399/J3490/etc.) codes require a corresponding National Drug Code (NDC) to be billed on all claims
    ScopeApplies to entries marked with the ‡ symbol throughout the medication list
    Examples in listSeveral agents (e.g., Rybrevant Faspro, Filkri entries) show C9399/J3490 style codes marked with ‡ requiring NDC

    How to Request Authorization and Provider Responsibilities

    Prior Authorization

    How to request prior authorization

    Prior authorization is required for certain services and medications. To request prior authorization for medications (except where otherwise noted), submit via one of the following methods: Online via CoverMyMeds (http://www.covermymeds.com/); Phone: 866-461-7273 (TTY: 711), Monday–Friday, 8 a.m. – 11 p.m., Eastern time; Fax: 888-447-3430. Request forms are available on Humana's prior authorization for professionally administered drugs website. For transplant-related preauthorization requests, see the separate transplant network submission guidance below.

    • Online: CoverMyMeds (http://www.covermymeds.com/)
    • Phone: 866-461-7273 (TTY: 711), Monday–Friday, 8 a.m. – 11 p.m., Eastern time
    • Fax: 888-447-3430 (Request forms available on Humana's prior authorization for professionally administered drugs website)
    Note

    Advance coverage determination (ACD)

    Humana may permit an Advance Coverage Determination (ACD) for investigational, experimental, or limited-benefit services or to determine coverage before providing a service. ACDs for medications on the list can be initiated by submitting a fax or phone request. You may be contacted if additional information is needed to complete the review.

    Note

    Urgent services and new member active treatment provision

    Urgent or emergent services do not require prior authorization. Additionally, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment. Humana may review services furnished during an active course of treatment when determining payment; include the appropriate modifier per Humana's Medicare Advantage Payment Policy or submit medical records showing the member is in an active course of treatment.

    • Urgent/emergent services are exempt from prior authorization
    • New member provision: 90-day active-treatment grace for services initiated prior to enrollment
    Denial Risk

    Denial and financial risk

    Failure to obtain required prior authorization may result in financial penalties to the provider and reduced patient benefits. Services or medications provided without required prior authorization may be subject to retrospective medical necessity review. Providers are encouraged to verify benefits and prior authorization requirements before providing services.

    • Not obtaining prior authorization may result in financial penalties and reduced patient benefits
    • Services provided without prior authorization may be subject to retrospective medical necessity review
    Documentation Required

    Required information for prior authorization or notification

    When submitting a prior authorization request or notification, include all required information to expedite determination. Submitting complete clinical documentation at the time of request reduces delays; Humana will contact the requester if additional information is needed.

    • Patient name, date of birth, and Humana member ID number
    • Date of actual service or hospital admission
    • HCPCS code(s) and diagnosis codes (primary and secondary) — up to 6 diagnosis codes per request
    • Service location (inpatient: acute hospital, skilled nursing, hospice; outpatient: telehealth, office, home, off-campus outpatient hospital, on‑campus outpatient hospital, ambulatory surgery center)
    • Tax Identification Number (TIN) and National Provider Identifier (NPI) of facility where service is rendered, and TIN and NPI of the provider performing the service
    • Caller/requester name and phone number and attending provider's phone number
    • Relevant clinical information and supporting documentation
    Step Therapy

    Medication prior authorization entries and flags

    Medication prior authorization entries in Humana's lists include brand and generic names, associated billing codes, and special flags. Flags indicate: new preauthorization requirement (*), new-to-market drug addition (†), shared HCPCS/NOC codes requiring an NDC on claims (‡), step therapy required through a Humana-preferred drug (**), and therapies reviewed by the Humana National Transplant Network (††). Providers must follow these flags when preparing PA requests and billing claims.

    • * New preauthorization requirement
    • † New-to-market drug addition
    • ‡ Shared HCPCS/NOC codes require a corresponding NDC on claims
    • ** Step therapy required through a Humana-preferred drug as part of preauthorization
    • †† Preauthorization requests routed to Humana National Transplant Network
    Billing Rule

    Prior authorization submission requirements and special flags

    Prior authorization submission requirements and special billing rules to note: all shared HCPCS and NOC codes require the corresponding NDC to be billed on claims; step therapy indicators (**) mean a Humana-preferred drug trial is required per the PA criteria; providers who do not stock a preferred medication may obtain it from a pharmacy (specialty or mail-order) to administer. Include NDC when applicable and follow Humana's coding and claims guidance to ensure appropriate payment.

    • All shared HCPCS/NOC codes require a corresponding NDC on claims
    • Step therapy (**) requires trial of a Humana‑preferred drug as part of preauthorization
    • If provider does not stock preferred medication, consider obtaining from a pharmacy (specialty or mail-order)
    • Include appropriate modifiers per Humana Medicare Advantage Payment Policy when applicable
    Note

    Transplant Network preauthorization submission

    Preauthorization requests for transplant-related items and therapies are reviewed by the Humana National Transplant Network. Submit transplant preauthorization requests by fax to 502-508-9300, by phone at 866-421-5663 (Monday–Friday, 7 a.m. – 7 p.m., Central time), or by email to transplant@humana.com. The transplant network will review and direct appropriate routing for these requests.

    • Fax: 502-508-9300
    • Phone: 866-421-5663, Monday–Friday, 7 a.m. – 7 p.m., Central time
    • Email: transplant@humana.com
    • Transplant-related PAs will be reviewed by the Humana National Transplant Network
    Note

    Medication-specific entry guidance

    Many medication-specific entries in Humana's PA list name the brand, generic, and billing codes — for example, brand name and corresponding J‑ or Q‑codes — along with the flags described above. Providers should reference the PA list entry for the medication in question and include the listed billing codes and required NDC information when submitting the request.

    • Medication entries include brand name, generic name, and billing codes (J‑codes/Q‑codes)
    • Follow medication-specific entry flags and billing code requirements when submitting PA
    Note

    General prior authorization request method and plan-specific forms

    For plan- or region-specific prior authorization and notification forms (for example, H1036-280 Humana Fully Integrated Florida HMO D‑SNP), access the indicated prior authorization and notification list and associated fax forms to request preauthorization or provide notification. Use the plan-specific forms when applicable.

    • Access plan-specific PA/notification lists and fax forms (e.g., H1036-280 Humana Fully Integrated Florida HMO D‑SNP) as indicated
    • Use plan-specific forms when submitting PA or notification

    Definitions and Flag Legend

    inv-22: prior authorization
    DefinitionPrior authorization (also called preauthorization or precertification): a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered
    PurposeEnsures services meet Medicare coverage guidelines and are medically necessary before being provided
    Also notedUsed for medications delivered in office, clinic, outpatient, or home settings listed on the PA list
    inv-23: advance coverage determination (ACD)
    DefinitionAdvance coverage determination (ACD): a request submitted on behalf of a patient to determine whether Humana will pay for a procedure or service prior to providing it
    When to useFor investigational, experimental, or limited-benefit services or to confirm payment before providing a service
    How to submitACDs for medications on the list can be initiated by fax or phone per provider instructions
    inv-24: step therapy
    DefinitionStep therapy: requirement that treatment begin with a Humana-preferred drug (a step) before coverage is approved for a nonpreferred agent as part of preauthorization
    FlagEntries requiring step therapy are marked with the ** symbol in the medication list
    ReferenceHumana's Medicare Part B Step Therapy Preferred Drug List may identify preferred and nonpreferred medications
    inv-25: NDC billing requirement
    RequirementAll shared HCPCS codes and not otherwise classified codes require a corresponding NDC to be billed on all claims
    NotationThese entries are indicated by the ‡ symbol in the medication list
    Affected codesApplies to C9399/J3490-style NOC entries and other shared HCPCS codes shown in the list
    inv-26: ‡ (NDC billing requirement)
    Symbol meaning‡ indicates that all shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims
    Where usedThe legend for the prior authorization list and multiple entry footnotes use this symbol to denote the NDC billing requirement
    Action for providersInclude the corresponding NDC on claims when billing HCPCS entries marked with ‡
    inv-27: ** (step therapy flag)
    Symbol meaning** indicates step therapy is required through a Humana-preferred drug as part of preauthorization
    UsageApplied to specific drug entries in the medication list to denote step therapy requirement
    Provider implicationFollow Humana's step therapy process and preferred-drug sequencing when submitting PA for agents marked **
    inv-28: †† (transplant review)
    Symbol meaning†† indicates preauthorization requests will be reviewed by the Humana National Transplant Network
    Submission methodsTransplant reviews can be submitted by fax to 502-508-9300, phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com
    Applies toTransplant-related drug entries in the medication list marked with ††
    inv-29: * (new preauthorization requirement)
    Symbol meaning* indicates a new preauthorization requirement
    PlacementUsed in the legend and next to drug entries to show newly added PA requirements
    Provider actionConfirm PA requirement for items marked with * before providing service
    inv-30: ‡ billing note
    Billing note (reiteration)Shared HCPCS codes and not otherwise classified codes require a corresponding NDC on all claims (entries marked with ‡)
    Why it mattersFailure to include the NDC when required may result in claim processing issues or denials
    Where indicatedThis billing note appears in the list legend and alongside many drug entries throughout the document
    inv-31: ** step therapy
    Reiteration** indicates step therapy is required through a Humana-preferred drug as part of preauthorization
    Flag locationRepeated in the legend and next to multiple medication entries
    ImplicationProviders should follow step therapy sequencing when submitting PA for entries marked **
    inv-32: †† transplant review
    Reiteration†† indicates preauthorization requests will be reviewed by the Humana National Transplant Network
    Contact detailsFax 502-508-9300; phone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. CT); email transplant@humana.com
    Where shownAppears in the legend and alongside transplant-related drug entries throughout the list
    inv-33: † new-to-market
    Symbol meaning† indicates a new-to-market drug addition
    UsageUsed in the list to denote recently introduced (new-to-market) agents
    Provider considerationBe aware of additional review or documentation that may accompany † entries
    inv-34: * new preauthorization requirement
    Symbol meaning (duplicate)* denotes a new preauthorization requirement when shown next to an entry
    Legend placementIncluded in the list legend and repeated across sections of the document
    ActionVerify PA is obtained for items newly marked with * prior to service